Donald P. Bottaro

Also affiliated with Center for Cancer Research

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

4in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 4 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Supplementary Figure from Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy

(2023)10.1158/1078-0432.22486571

Top 100%

0DataRank

Top 100%0 citations

Scot A. Niglio, Amir Mortazavi, Rosa Nadal, Primo N. Lara, Sumanta K. Pal +30 more

Papers

Driven by 23 papers — median percentile 0. Top paper: “Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors”.

Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors

Journal of Clinical Oncology(2020)10.1200/jco.20.01652

N/A

3.5DataRank · unranked

138 citations

Rosa Nadal, Daniel M. Girardi, Scot A. Niglio, Lisa Ley, Lisa M. Cordes +30 more

Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial

The Lancet Oncology(2020)10.1016/s1470-2045(20)30202-3

N/A

3.0DataRank · unranked

89 citations

Rosa Nadal, Yusuke Tomita, Nicole N. Davarpanah, Lisa M. Cordes, Seth M. Steinberg +27 more

Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-3726

N/A

1.1DataRank · unranked

24 citations

Scot A. Niglio, Amir Mortazavi, Rosa Nadal, Primo Lara, Sumanta K. Pal +30 more

Combination therapy with pazopanib and tivantinib modulates VEGF and c-MET levels in refractory advanced solid tumors

Investigational New Drugs(2021)10.1007/s10637-021-01138-x

N/A

0.312DataRank · unranked

7 citations

Apurva K. Srivastava, Tony Navas, Fabiola Cecchi, Young Ho Lee, Donald P. Bottaro +11 more

Phase I expansion study of cabozantinib plus nivolumab (CaboNivo) in metastatic urothelial carcinoma (mUC) patients (pts) with progressive disease following immune checkpoint inhibitor (ICI) therapy.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.5037

N/A

0DataRank · unranked

2 citations

Scot A. Niglio, Amir Mortazavi, Primo Lara, Sumanta K. Pal, Biren Saraiya +15 more

Autocrine Signaling by Receptor Tyrosine Kinases in Urothelial Carcinoma of the Bladder

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.10.15.341206

N/A

0DataRank · unranked

0 citations

Molly M. Lee, Dinuka M. De Silva, Arpita Singha Roy, Cara E. Wright, Tiffany K. Wong +7 more

Faculty Opinions recommendation of Genetic Variants of VEGFA and FLT4 Are Determinants of Survival in Renal Cell Carcinoma Patients Treated with Sorafenib.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature(2020)10.3410/f.734354702.793578561

N/A

0DataRank · unranked

0 citations

Donald P. Bottaro

Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue Sarcomas

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-2480

N/A

0DataRank · unranked

27 citations

Shivaani Kummar, James Hu, Kristen Ganjoo, Warren A. Chow, Khanh T. Do +17 more

Autocrine signaling by receptor tyrosine kinases in urothelial carcinoma of the bladder

PLoS ONE(2021)10.1371/journal.pone.0241766

N/A

0DataRank · unranked

7 citations

Molly M. Lee, Dinuka M. De Silva, Arpita Singha Roy, Cara E. Wright, Tiffany K. Wong +7 more

Final results from a phase I trial and expansion cohorts of cabozantinib and nivolumab (CaboNivo) alone or with ipilimumab (CaboNivoIpi) for metastatic genitourinary tumors.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.6_suppl.3

N/A

0DataRank · unranked

9 citations

Daniel M. Girardi, Scot A. Niglio, Rosa Maria Nadal, Lisa M. Cordes, Seth M. Steinberg +15 more

Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary Cancer

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-2891

N/A

0DataRank · unranked

48 citations

Tiziano Pramparo, Amir Mortazavi, Scot A. Niglio, Joseph D. Schonhoft, Adam Jendrisak +26 more

Inhibition of HSP 90 is associated with potent anti-tumor activity in Papillary Renal Cell Carcinoma

Journal of Experimental & Clinical Cancer Research(2022)10.1186/s13046-022-02416-z

N/A

0DataRank · unranked

13 citations

Janhavi Dubhashi, Anand Singh, Parthav Jailwala, Alexei Lobanov, Craig J. Thomas +10 more

Regression of Human Breast Carcinoma in Nude Mice after Adsflt Gene Therapy Is Mediated by Tumor Vascular Endothelial Cell Apoptosis

Cancers(2022)10.3390/cancers14246175

N/A

0DataRank · unranked

2 citations

Donald P. Bottaro, Antonella Mangoni, Petra Reusch, Dieter Marmé, Imre Kovesdi +5 more

Rilotumumab Resistance Acquired by Intracrine Hepatocyte Growth Factor Signaling

Cancers(2023)10.3390/cancers15020460

N/A

0DataRank · unranked

5 citations

Karen Rex, Joanna Schmidt, Cathy D. Vocke, Young Ho Lee, Sandra Burkett +6 more

Hepatocyte Growth Factor

Zenodo (CERN European Organization for Nuclear Research)(2023)10.5281/zenodo.7629916

N/A

0DataRank · unranked

2 citations

Donald P. Bottaro, Jeffrey S. Rubin

Supplementary Figure from Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy

(2023)10.1158/1078-0432.22486571

Top 100%

0DataRank

Top 100%0 citations

Scot A. Niglio, Amir Mortazavi, Rosa Nadal, Primo N. Lara, Sumanta K. Pal +30 more

Supplementary Figure from Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy

Figshare(2023)10.1158/1078-0432.22486556.v1

Top 100%

0DataRank

Top 100%0 citations

Scot A. Niglio, Amir Mortazavi, Rosa Nadal, Primo N. Lara, Sumanta K. Pal +30 more

Data from Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary Cancer

(2023)10.1158/1078-0432.c.6529986

N/A

0DataRank · unranked

0 citations

Tiziano Pramparo, Amir Mortazavi, Scot A. Niglio, Joseph D. Schonhoft, Adam Jendrisak +26 more

Data from A Phase I/II Multicenter Study of Single-Agent Foretinib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma

(2023)10.1158/1078-0432.c.6526233.v1

N/A

0DataRank · unranked

0 citations

Riccardo Lencioni, Wattana Sukeepaisarnjaroen, Yee Chao, Chia‐Jui Yen, Wirote Lausoontornsiri +13 more

Data from Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy

(2023)10.1158/1078-0432.c.6532346.v1

Top 100%

0DataRank

Top 100%0 citations

Scot A. Niglio, Amir Mortazavi, Rosa Nadal, Primo N. Lara, Sumanta K. Pal +30 more

Final results from a phase 1 trial and expansion cohorts of cabozantinib and nivolumab alone or with ipilimumab for advanced/metastatic genitourinary tumors

Research Square(2023)10.21203/rs.3.rs-2924051/v1

N/A

0DataRank · unranked

0 citations

Scot A. Niglio, Rosa Nadal, Andre R. Kydd, Nicholas I. Simon, Lisa Ley +36 more

Ipilimumab challenge/re-challenge in metastatic urothelial carcinoma (mUC) and other genitourinary (GU) tumors treated with cabozantinib+nivolumab (CaboNivo) or cabozantinib+nivolumab+ipilimumab (CaboNivoIpi).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.5039

N/A

0DataRank · unranked

3 citations

Daniel M. Girardi, Amir Mortazavi, Primo N. Lara, Sumanta K. Pal, Biren Saraiya +15 more

The Processing and Transport of Peptide Hormones Across Endothelial Cell Barriers

Insulin, Insulin-like Growth Factors, and Their Receptors in the Central Nervous System(1987)10.1007/978-1-4684-5380-5_4

N/A

0DataRank · unranked

0 citations

George L. King, Donald P. Bottaro

Donald P. Bottaro

Indexed papers

Top data-sharing exemplar

Papers